Abstract:Importance: Antidepressant use is increasing worldwide. Yet, contrasting evidence on the safety of antidepressants is available from meta-analyses, and the credibility of these findings has not been quantified. Objective: To grade the evidence from published meta-analyses of observational studies that assessed the association between antidepressant use or exposure and adverse health outcomes. Data sources: PubMed, Scopus, and PsycINFO were searched from database inception to April 5, 2019. Evidence review: Only meta-analyses of observational studies with a cohort or case-control study design were eligible. Two independent reviewers recorded the data and assessed the methodological quality of the included meta-analyses. Evidence of association was ranked according to established criteria as follows: convincing, highly suggestive, suggestive, weak, or not significant. Results: Forty-five meta-analyses (17.9%) from 4471 studies identified and 252 full-text articles scrutinized were selected that described 120 associations, including data from 1012 individual effect size estimates. Seventy-four (61.7%) of the 120 associations were nominally statistically significant at P ≤ .05 using random-effects models. Fifty-two associations (43.4%) had large heterogeneity (I2 > 50%), whereas small-study effects were found for 17 associations (14.2%) and excess significance bias was found for 9 associations (7.5%). Convincing evidence emerged from both main and sensitivity analyses for the association between antidepressant use and risk of suicide attempt or completion among children and adolescents, autism spectrum disorders with antidepressant exposure before and during pregnancy, preterm birth, and low Apgar scores. None of these associations remained supported by convincing evidence after sensitivity analysis, which adjusted for confounding by indication. Conclusions and relevance: This study's findings suggest that most putative adverse health outcomes associated with antidepressant use may not be supported by convincing evidence, and confounding by indication may alter the few associations with convincing evidence. Antidepressant use appears to be safe for the treatment of psychiatric disorders, but more studies matching for underlying disease are needed to clarify the degree of confounding by indication and other biases. No absolute contraindication to antidepressants emerged from this umbrella review.

A leaky umbrella has little value: evidence clearly indicates the serotonin system is implicated in depression

The involvement of serotonin in major depression: nescience in disguise?

Methodological concerns in umbrella review of serotonin and depression

Letter to the editor concerning: "The serotonin theory of depression: a systematic umbrella review of the evidence"

The neurobiology of depression—revisiting the serotonin hypothesis. II. Genetic, epigenetic and clinical studies

Serotonergic vulnerability and depression: assumptions, experimental evidence and implications

The role of serotonin in depression—A historical roundup and future directions

Serotonin is a common thread linking different classes of antidepressants

The Benefits and Risks of 5-HT Uptake Inhibitors in Depression: Chairman's Introduction

Serotonin and depression: pathophysiological mechanism or marketing myth?

Peripheral serotonin levels as a predictor of antidepressant treatment response: A systematic review

Serotonin in depression and Alzheimer's disease: Focus on SSRI's beneficial effects

Revisiting the Serotonin Hypothesis: Implications for Major Depressive Disorders

5-HT and depression: is the glass half-full?

Deficient serotonin neurotransmission and depression-like serotonin biomarker alterations in tryptophan hydroxylase 2 (Tph2) loss-of-function mice

Association of Antidepressant Use With Adverse Health Outcomes: A Systematic Umbrella Review

The neurobiology of depression—revisiting the serotonin hypothesis. I. Cellular and molecular mechanisms

Serotonin-immune Interactions in Major Depression: Lower Serum Tryptophan As a Marker of an Immune-Inflammatory Response

Serum neuroactive metabolites of the tryptophan pathway in patients with acute phase of affective disorders

Modulation of the Serotonergic Receptosome in the Treatment of Anxiety and Depression: A Narrative Review of the Experimental Evidence